ACRIN 6666 Screening Breast US Follow-up Assessment Form
|
|
- Stuart Hall
- 5 years ago
- Views:
Transcription
1 Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related t the time perid, e.g. imaging, bipsy, surgery and/r nn-prtcl related treatment. The frm is cmpleted whether r nt there was any activity and is designed primarily t capture imaging and bipsy events at facilities ther than the study imaging site. Include nly items that have nt previusly been reprted. NOTE: Fr a "6-mnth" fllw-up (perfrmed at study site) after any annual exam, cmplete frm F6 instead f, fr additinal views use IM, fr cre bipsies use BX, etc. 1. Time pint f this fllw-up 12 mnths 24 mnths 36 mnths 1a. Recrd actual elapsed mnths since study entry 2. Date f fllw-up cntact r attempt Methd f cntact At appintment By telephne 4. Participant Status Alive (prceed t Q5) Dead (cmplete Q4a) Lst t fllw-up; unable t cntact (prceed t Q4b) 4a. Date f death - - If date f death unknwn cde If exact date is unknwn, chse the 15th f that mnth. 4b. Date f last cntact - - Sectin I. Clinical Status 5. Was a clinical breast exam f the breast(s) perfrmed since the last annual screening visit? N (prvide reasn in Q5a) Yes (cmplete then prceed t Q5b and Q5c) Right (cmplete Qs 5b and 5c) Left (cmplete Qs 5b and 5d) Bth (cmplete Qs 5b-5d) Unknwn (prceed t Q6) 5a. Prvide reasn CBE nt dne (then prceed t Q6): Patient missed appintment Patient unable t be lcated Patient pregnant r lactating Patient refused Referring physician's chice Expired 5b. Date f fllw-up CBE - mm Fr revised r crrected frm:check bx and fax t yyyy 5c. Have there been any clinically significant changes in the right breast since the last annual examinatin? N r breast nt n study Yes (check all clinical changes that apply) Palpable mass (cmplete lcatin) Lcatin f abnrmality 'clck r specify lcatin: Axilla Retrarelar Unknwn Nipple discharge (detail): Bldy Clear spntaneus Other Other, specify: 5d. Have there been any clinically significant changes in the left breast since the last annual examinatin? N r breast nt n study Yes (check all clinical changes that apply) Palpable mass (cmplete lcatin) Lcatin f abnrmality 'clck r specify lcatin: Axilla Retrarelar Unknwn Nipple discharge (detail): Bldy Clear spntaneus Other Other, specify: 6. Current use f hrmnes? N (prceed t Q7) Yes (cmplete Q6a) 6a. Specify hrmne(s) 7. Has any interval breast imaging been perfrmed since last visit? (cnsider nly items nt previusly reprted n frms IM, F6, etc., per instructins.) N (prceed t Sectin III) Yes (cmplete Q7a) 7a. Check all breast imaging perfrmed since last visit: Mammgram (cmplete Q8) Ultrasund (cmplete Q11) MRI (cmplete Q14) Other (cmplete Q17) D nt recall details (prceed t Q20) "Cpyright 2005" f 5
2 Fr revised r crrected frm, check bx and fax t Sectin II. Interval Imaging N. 8. Mammgram (If n mammgram perfrmed prceed t Q11) Identify the study breast(s) n which a mammgram was perfrmed in the past 11 mnths. NOTE: Interval mammgraphy at study site shuld be reprted n frms IM and/r F6 as apprpriate. Right (Cmplete Qs 8a, 8b and 9) Left (Cmplete Qs 8a, 8b and 10) Bth (Cmplete Qs 8a-10a) 8a. Date f mst recent mammgram - mm yyyy 8b. Specify basis fr decisin t btain the Mammgram Recmmended by: MD wh referred yu fr screening Anther physician (identify type f physician) Surgen Other r unknwn Smene else (specify relatinship f this persn t yu) 9. Mammgraphic Assessment f Right Breast If N evaluatin f Right Breast perfrmed, prceed t Q10 If utside study cdes "4, suspicius", cde as 4B. 9a. Reprted Assessment fr right breast 1 Negative 2 Benign 3 Prbably Benign 4A Lw Suspicin f Malignancy 4B Intermediate Suspicin 4C Mderately High Suspicin 5 Highly Suggestive f Malignancy Assessment unknwn r incmplete (unable t btain reprted assessment, dne at anther imaging facility, BIRADS 0, r partial reprt) 10. Mammgraphic Assessment f Left Breast If N evaluatin f Left Breast perfrmed, prceed t Q11 If utside study cdes "4, suspicius", cde as 4B 10a. Reprted Assessment fr left breast 1 Negative 2 Benign 3 Prbably Benign 4A Lw Suspicin f Malignancy 4B Intermediate Suspicin 4C Mderately High Suspicin 5 Highly Suggestive f Malignancy Assessment unknwn r incmplete (unable t btain reprted assessment, dne at anther imaging facility, BIRADS 0, r partial reprt) 11. Ultrasund (If n ultrasund perfrmed prceed t Q14) Identify the study breast(s) n which an Ultrasund was perfrmed in the past 11 mnths. NOTE: Interval ultrasund at study site shuld be reprted n frms IM and/r F6 as apprpriate. Right (Cmplete Qs 11a, 11b and 12) Left (Cmplete Qs 11a, 11b and 13) Bth (Cmplete Qs 11a-13a) 11a. Date f mst recent ultrasund - 11b. Specify basis fr decisin t btain the Ultrasund Recmmended by: MD wh referred yu fr screening Anther physician (identify type f physician) Surgen Other r unknwn Smene else (specify relatinship f this persn t yu) 12. Ultrasund Assessment f Right Breast If N evaluatin f Right Breast perfrmed, prceed t Q13 If utside study cdes "4, suspicius", cde as 4B 12a. Assessment fr right breast 1 Negative 2 Benign 3 Prbably Benign 4A Lw Suspicin f Malignancy 4B Intermediate Suspicin 4C Mderately High Suspicin 5 Highly Suggestive f Malignancy Assessment unknwn r incmplete (unable t btain reprted assessment, dne at anther imaging facility, BIRADS 0, r partial reprt) 13. Ultrasund Assessment f Left Breast If N evaluatin f Left Breast perfrmed, prceed t Q14 If utside study cdes "4, suspicius", cde as 4B 13a. Assessment fr left breast 1 Negative 2 Benign 3 Prbably Benign 4A Lw Suspicin f Malignancy 4B Intermediate Suspicin 4C Mderately High Suspicin 5 Highly Suggestive f Malignancy Assessment unknwn r incmplete (unable t btain reprted assessment, dne at anther imaging facility, BIRADS 0, r partial reprt) "Cpyright 2005" f 5
3 Fr revised r crrected frm, check bx and fax t Cntrast-enhanced breast MRI (If n breast MRI perfrmed prceed t Q17) Identify the study breast(s) n which an MRI was perfrmed in the past 11 mnths? Right (Cmplete Qs 14a, 14b, and 15) Left (Cmplete Qs 14a, 14b and 16) Bth (Cmplete Qs 14a-16a) 14a. Date f mst recent breast MRI - 14b. Specify basis fr decisin t btain the MRI Recmmended by: MD wh referred yu fr screening Anther physician (identify type f physician) Surgen Other r unknwn Smene else (specify relatinship f this persn t yu) 15. MRI Assessment f Right Breast If N evaluatin f Right Breast perfrmed, prceed t Q16 If utside study cdes as "4, suspicius", cde as 4B 15a. Assessment fr right breast 1 Negative 2 Benign 3 Prbably Benign 4A Lw Suspicin f Malignancy 4B Intermediate Suspicin 4C Mderately High Suspicin 5 Highly Suggestive f Malignancy Assessment unknwn r incmplete (unable t btain reprted assessment, dne at anther imaging facility, BIRADS 0, r partial reprt) 16. MRI Assessment f Left Breast If N evaluatin f Left Breast perfrmed, prceed t Q17 If utside study cdes as "4, suspicius", cde as 4B 16a. Assessment fr left breast 1 Negative 2 Benign 3 Prbably Benign 4A Lw Suspicin f Malignancy 4B Intermediate Suspicin 4C Mderately High Suspicin 5 Highly Suggestive f Malignancy Assessment unknwn r incmplete (unable t btain reprted assessment, dne at anther imaging facility, BIRADS 0, r partial reprt) N. 17. Other Breast Imaging (If n ther breast imaging perfrmed prceed t sectin III) Identify ther imaging perfrmed f the study breast(s) perfrmed in the past 11 mnths. NOTE: Use frms IM r F6 t reprt additinal mammgraphic r sngraphic imaging at this site as apprpriate Right (Cmplete Qs 17a, 17b, 17c and 18) Left (Cmplete Qs 17a, 17b, 17c and 19) Bth (Cmplete Qs 17a-19a) Unknwn (prceed t Q20) 17a. Specify type 17b. Date f mst recent ther imaging - 17c. Specify basis fr decisin t btain ther imaging Recmmended by: MD wh referred yu fr screening Anther physician (identify type f physician) Surgen Other r unknwn Smene else (specify relatinship f this persn t yu) 18. Other Imaging Assessment f Right Breast If N evaluatin f Right Breast perfrmed, prceed t Q19 If utside study cdes as "4, suspicius", cde as 4B 18a. Assessment fr right breast 1 Negative 2 Benign 3 Prbably Benign 4A Lw Suspicin f Malignancy 4B Intermediate Suspicin 4C Mderately High Suspicin 5 Highly Suggestive f Malignancy Assessment unknwn r incmplete (unable t btain reprted assessment, dne at anther imaging facility, BIRADS 0, r partial reprt) 19. Other Imaging Assessment f Left Breast If N evaluatin f Left Breast perfrmed, prceed t Q20 If utside study cdes as "4, suspicius", cde as 4B 19a. Assessment fr left breast 1 Negative 2 Benign 3 Prbably Benign 4A Lw Suspicin f Malignancy 4B Intermediate Suspicin 4C Mderately High Suspicin 5 Highly Suggestive f Malignancy Assessment unknwn r incmplete (unable t btain reprted assessment, dne at anther imaging facility, BIRADS 0, r partial reprt) "Cpyright 2005" f 5
4 Fr revised r crrected frm, check bx and fax t Sectin III. Interventin 20. Were there any cyst aspiratins, bipsies r surgeries n the study breast(s) in the past 11 mnths? N (Prceed t Q21) Yes, nt previusly reprted (Cmplete Q20a) Yes, previusly reprted (Prceed t Q21) Unknwn (Prceed t Q21) NOTE: If yes and the prcedures have nt previusly been reprted, cmplete Q20a and Frm(s) BX, NL, and S1 as apprpriate. Sectin IV. Summary/Treatment N. 21. Was a breast cancer diagnsed in the past 11 mnths? N (Cmplete Q21a) Yes, nt already reprted (Prceed t Q21b and cmplete BX and S1 frms) Yes, already reprted n BX and/r, NL and S1 (Prceed t Q22) Unknwn (Prceed t Q22) 20a. Specify interventin and date (list all that apply belw) If an interventin is n bth breasts, list each breast n a separate line. Interventin Cde Table (Q20a) 1 Cyst Aspiratin 2 FNAB (cmplete BX) 3 Cre Needle Bipsy (cmplete BX) 4 Excisinal Bipsy (cmplete NL) 5 Lumpectmy (cmplete S1) 6 Sentinel Lymph Nde (cmplete S1) 7 Axillary Lymph Nde Dissectin (cmplete S1) 8 Mastectmy (cmplete S1) 10 Other, specify (in details) 99 Specifics Unknwn Interventin Date (mm-yyyy) Details R L N/A a. Mst reliable surce regarding Negative breast cancer status fr this participant. (cmplete then prceed t Q22) Participant herself says she has nt been diagnsed with breast cancer N findings reprted in participant's medical chart Participant's Primary Care Physician (PCP) (n abnrmality fund at last clinical exam) Reprt f clinical exam Other Physician (n abnrmality fund at last clinical exam) Relative r friend stated that participant has nt been diagnsed with breast cancer Participant is nt listed n the cancer registry fr the area in which she lives Hspital billing department reprts n charges fr breast cancer treatment 21b. Mst reliable surce regarding Psitive breast cancer status fr this participant. Pathlgy reprt Cancer diagnsis is reprted in participant's medical chart Participant's Primary Care Physician (PCP) reprts breast cancer Participant herself says she has been diagnsed with breast cancer Death certificate in municipality f last knwn address that lists cause f death as breast cancer Relative r friend states that participant has been diagnsed with breast cancer Participant is listed n the cancer registry fr the area in which she lives Hspital billing department reprts charges fr breast cancer treatment 21c. Site f breast cancer Right Left Bilateral "Cpyright 2005" f 5
5 Fr revised r crrected frm, check bx and fax t Additinal treatment fr disease f the study breast(s) N (Prceed t Q23) Yes, nt previusly reprted (Cmplete Q22a) Yes, previusly reprted (Prceed Q23) Unknwn (Prceed t Q23) NOTE: Reprt all treatment that is cntinuing r new since last cntact. Prvide the start date fr each, details and site. 22a. Specify treatment and date (list all that apply belw) If an interventin is n bth breasts, list each breast n a separate line. N. Interventin Cde Table (Q22a) 1 Radiatin Therapy 2 Systemic Chemtherapy 3 Other hrmne manipulatin 9 Other, specify (in details) 99 Specifics Unknwn Interventin Date (mm-yyyy) Details R L N/A Has patient enrlled int a breast imaging trial in the past 11 mnths ther than the Screening Breast Ultrasund in High Risk Wmen Trial? N (Stp and sign frm) Yes (Cmplete Q23a) Unknwn (Stp and sign frm) 23a. Prvide name f trial Cmments: Signature f persn respnsible fr the data Date Frm Cmpleted (mm-dd-yyyy) Signature f persn entering data nt web 2 "Cpyright 2005" f 5
Background 1. Definition Fibroadenoma: Group of hyperplastic breast lobules composed of stromal and epithelial elements
Fibradenma Backgrund 1. Definitin Fibradenma: Grup f hyperplastic breast lbules cmpsed f strmal and epithelial elements Simple benign slid tumrs with glandular and fibrus tissue Cmplex Scleringadensis
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationNonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer
Nnclinical factrs assciated with premature terminatin f adjuvant chemtherapy fr stage I-III breast cancer Xia-Cheng Wu, Trevr Thmpsn, Meichin Hsieh, Meijia Zhu, Patricia Andrews, Michelle Lch, Timthy Styles,
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationNPCR CLINICAL EDIT CHECKS
NPCR CLINICAL EDIT CHECKS FCDS Annual Meeting July 26, 2013 Sunrise, Flrida Steven Peace, CTR FCDS Data Quality Staff PURPOSE OF CLINICAL EDIT CHECKS The primary purpse f the Clinical Check edits is t
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More information2. How are screening and diagnostic mammograms different?
Mammgrams cmprises public dmain material frm the Natinal Cancer Institute at the Natinal Institutes f Health, an agency f the U.S. Department f Health and Human Services. Mammgrams Key Pints A mammgram
More informationFOLLOW-UP IN-DEPTH INTERVIEW GUIDELINES
Appendix h STUDY NUMBER: COST OF UNSAFE ABORTION FOLLOW-UP IN-DEPTH INTERVIEW GUIDELINES T be administered abut 2-3 weeks after leaving the health facility 1. IDENTIFICATION 101. Patient identificatin
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationA foot x-ray series is required only if there is pain in the midfoot zone and any one of the following:
RADIOGRAPHY OF THE ANKLE AND FOOT (OTTAWA ANKLE RULES) Clinical Practice Guideline January 2007 This guideline has been adapted frm the Ottawa Ankle Rules develped by Dr. Ian Stiell et al. Dr. Stiell received
More informationPROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS
PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationDental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.
Dental Benefits Under the TeamstersCare Plan, yu and yur eligible dependents have three basic ptins when yu need dental care. Optin #1: TeamstersCare Dentists. Yu can use ur in-huse Charlestwn, Chelmsfrd,
More informationNational Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes
Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.3 Cmpleted: June 15, 2017 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationHuon Logistics Isolation & Lockout Work Instruction 1. LOCKOUT DEVICES 2. LIGHT VEHICLE POSITIVE ISOLATION POINTS - 1 -
Hun Lgistics Islatin & Lckut Wrk Instructin Prcedure 1. LOCKOUT DEVICES Explanatin When an islatin f any mbile plant r equipment is required befre safe access t a machine can be prvided the fllwing must
More informationThe Mental Capacity Act 2005; a short guide for the carers and relatives of those who may need support. Ian Burgess MCA Lead 13 February 2017
The Mental Capacity Act 2005; a shrt guide fr the carers and relatives f thse wh may need supprt Ian Burgess MCA Lead 13 February 2017 Agenda Overview f the MCA The 5 Principles and the legal definitin
More informationUniversity College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service
University Cllege Hspital Pump schl Starting n an insulin pump Children and Yung Peple s Diabetes Service 2 If yu wuld like this dcument in anther language r frmat, r require the services f an interpreter,
More informationHospital Preparedness Checklist
Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been
More informationReference: Patient A. Brenda WXXXXX Date of Birth: 4/15/57
Reference: Patient A Brenda WXXXXX Date f Birth: 4/15/57 49 year ld white female patient presented n July 20, 2006 with chief cmplaint f stage 4 cancer, initially diagnsed in Octber, 2003 with Cervical
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationAnnual Principal Investigator Worksheet About Local Context
Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More information1-YEAR HIP FOLLOW-UP. Thank you for your attention to this matter. If you have any questions, please contact us for assistance. Thomas P.
1-YEAR HIP FOLLOW-UP It is imprtant t review the status f yur hip implant(s) during an ffice visit at six weeks, ne year, tw years, and every ther year pstperatively thereafter fr yur safety even thugh
More informationPodcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10
Pdcast Transcript Title: Cmmn Miscding f LARC Services Impacting Revenue Speaker Name: Ann Finn Duratin: 00:16:10 NCTCFP: Welcme t this pdcast spnsred by the Natinal Clinical Training Center fr Family
More informationBefore Your Visit: Mohs Skin Cancer Surgery
Befre Yur Visit: Mhs Skin Cancer Surgery Yur Kaiser Permanente Care Instructins Skin Cancer Infrmatin What is skin cancer? Skin cancers are tumrs, r malignancies, f the skin. Skin cancer is assciated with
More informationGuideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations
Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT INJECTIONS OR BLOCKS CPT Cdes: Cervical Thracic Regin: 64490 (+ 64491, +64492), 0213T (+0214T, +0215T) Lumbar Sacral Regin:
More informationFee Schedule - Home Health Care- 2015
Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule
More informationCoding. Training Guide
Cding (Specialty Hspital) Visin 4.3 (January 2013) Training Guide SurceMedical VisinSH Cding Learning Center f Excellence Last change made: January 2013 2013 Surce Medical Slutins, Inc. All Rights Reserved.
More informationCreating and Linking Charge Objects
Overview Charge bject screens are used t maintain cst accunting cdes that agencies use t break ut emplyee time based n wrk perfrmed and leave time while assigned t a specific prject(s). The charge bject
More informationIndications and Limitations of Coverage and/or Medical back to top
Fr services perfrmed n r after 09/15/2009 Original Determinatin Ending Date Revisin Effective Date Revisin Ending Date Indicatins and Limitatins f Cverage and/r Medical Necessity Indicatins Medicare cverage
More informationSection 5. Study Procedures
Sectin 5. Study Prcedures 5.1 Visit Lcatins... 1 5.2 Eligibility Determinatin... 1 5.3 Screening Visit... 2 5.3.1 Screening and Enrllment Timeframe... 2 5.3.2 Screening Visit Prcedures... 2 5.3.3 Screening
More informationSchool Medication Authorization Form. School Grade Teacher. Emergency Phone No: To be completed by the student's physician: Name of Medication:
Schl Medicatin Authrizatin Frm Student's Name Address Birth Date Hme Phne Schl Grade Teacher Emergency Phne N: T be cmpleted by the student's physician: Name f Medicatin: Dsage Frequency Time t be given
More informationQUALITY AND SAFETY MEASURES UPDATE January 2016
CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:
More informationField Epidemiology Training Program
Field Epidemilgy Training Prgram Cancer Curriculum: Principles f Cancer Registries Case Study: Hspital-Based Cancer Registries FACILITATOR GUIDE FETP Cancer Curriculum: Principles f Cancer Registries Case
More informationSUFFOLK COUNTY COUNCIL. Anti- Social Behaviour Act Penalty Notice. Code of conduct
SUFFOLK COUNTY COUNCIL Anti- Scial Behaviur Act 2003 Penalty Ntice Cde f cnduct SCC Penalty Ntice Cde f Cnduct & Administrative Guidance: revised August 2014 1 Cntents 1. Legal Basis 2. Purpse f the Penalty
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationHEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8
HEDIS Healthcare Effectiveness Data & Infrmatin Set (HEDIS ) The HEDIS â audit cntains a cre set f perfrmance measures that prvide infrmatin abut custmer satisfactin, specific health care measures, and
More informationFirst, you need to set up your MR filter as illustrated below o Log into Imagecast
HOW TO USE PROTOCOL MANAGER FOR BODY MRI CASES First, yu need t set up yur MR filter as illustrated belw Lg int Imagecast n First, click Wrklist Next, click Prtcl Finally, click filters. When yu d, the
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationThis standard operating procedure applies to stop smoking services provided by North 51.
Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue
More informationLower Extremity Amputation (LEA) Considerations / Issues
Lwer Extremity Amputatin (LEA) Cnsideratins / Issues Prviding Te Fillers can be an advantageus resurce fr yur patient and business but it als cmes with certain cnsideratins. Please review this list belw
More informationPatient Name: Address City State Zip Code. H. Phone W. Phone Cell Phone
Name yu prefer t g by: Address City State Zip Cde H. Phne W. Phne Cell Phne Email Address: Sex: M F Date f Birth Age Marital Status: M S D W Spuse s Name if Married: Scial Security # Referred by: Persn
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationUNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.
Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC
More informationFTD RESEARCH: The Value of Studies and Opportunities for Involvement
FTD RESEARCH: The Value f Studies and Opprtunities fr Invlvement Sarah Lawrence, MS Research Prgram Manager Ann Fishman, MBA Sr. Research Crdinatr Weiyi Mu, ScM Genetic Cunselr Suzanne Dana Spuse/Caregiver
More informationMale patients with pain, swelling or erythema please refer to the Acute Painful Scrotum pathway Female patients
UNDESCENDED TESTICLE ALGORITHM Unilateral undescended testicle OR Bilateral palpable undescended testicle Inclusin Criteria: Male patients w/ unilateral r bilateral undescended testicle(s) Exclusin Criteria:
More informationIndirect Sales. Proof Policy. Indirect Channel. Version May Author: Credit Risk & Fraud. External version
Prf Plicy Indirect Channel Versin 12 7 May 2015 Authr: Credit Risk & Fraud External versin 1 Table f Cntents Intrductin... 3 Distance Selling... 4 Face t Face Selling... 10 Additinal Prfs Plicy Infrmatin...
More information2017 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening and Fllw- Measure Steward: CMS Web Interface V1.0 Page 1 f 23 11/15/2016 Cntents INTRODUCTION... 3 WEB
More informationCambridge Breast Unit Protocols for anticoagulant management prior to breast or axillary biopsies or excisions.
Prtcl CBU/POL/ JOINT POLICIES/008 Octber 2017 Prtcls fr anticagulant management prir t breast r axillary bipsies r excisins. 1. Scpe Fr use in the in bth screening and symptmatic breast services. 2. Purpse
More informationMeaningful Use Roadmap Stage Edition Eligible Hospitals
Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing
More informationEXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS
1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationPage 1 of 5. Fast Facts. CTC v.4; AJCC 7 th ed. Herceptin provided
Page 1 f 5 NSABP B-47 - A Randmized Phase III Trial f Adjuvant Therapy Cmparing Chemtherapy Alne (Six Cycles f Dcetaxel Plus Cyclphsphamide r Fur Cycles f Dxrubicin Plus Cyclphsphamide Fllwed by Weekly
More informationPROVIDER ALERT. Comprehensive Diagnostic Evaluation (CDE) Guidelines to Access the Applied Behavior Analysis (ABA) Benefit.
Cmprehensive Diagnstic Evaluatin (CDE) Guidelines t Access the Applied Behavir Analysis (ABA) Benefit May 5, 2017 Clinical infrmatin that utlines medical necessity is required t supprt the need fr initial
More informationQ. Questions for paediatric audiology services: 2018/19
Q. Questins fr paediatric audilgy services: 2018/19 Please cmplete this survey if yur audilgy service prvides diagnstic hearing assessments and hearing aid prvisin fr children. This may be hspital r cmmunity
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More information2017 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Fllw-Up Measure Steward: CMS Web Interface V1.0 Page 1 f 22 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More information2018 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 23 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationPatrick J McGahan, MD Orthopaedic Surgeon Specializing in Sports Medicine/Shoulder Reconstruction Surgery Instructions Hip
Patrick J McGahan, MD Orthpaedic Surgen Specializing in Sprts Medicine/Shulder Recnstructin 2801 K St, Ste 330, Sacrament, CA, 95816 (p) 916-733-5049 (f) 916-733-8914 www.patrickmcgahanmd.cm Befre Surgery
More informationInstructions and Helpful Information for D-5 Form. Preliminary Approval of Dissertation and Request for Oral Defense (D-5)
Instructins and Helpful Infrmatin fr D-5 Frm Preliminary Apprval f Dissertatin and Request fr Oral Defense (D-5) 1. DEADLINES D-5 must be submitted t the UGS at least 3 WEEKS BEFORE the date f the defense
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationBenefits to Change for Diagnostic and Surgical/Reconstructive Breast Therapies and Corrective Procedures January 1, 2016
Benefits t Change fr Diagnstic and Surgical/Recnstructive Breast Therapies and Crrective Prcedures January 1, 2016 Infrmatin psted Nvember 13, 2015 Effective fr dates f service n r after January 1, 2016,
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More information2018 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.0 Page 1 f 23 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationYear 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:
Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:
More informationRecord of Revisions to Patient Tracking Spreadsheet Template
Recrd f Revisins t Patient Tracking Spreadsheet Template Belw is a recrd f revisins made by the AIMS Center t the Patient Tracking Spreadsheet Template. The purpse f this dcument is t infrm spreadsheet
More informationRoche Modular Auto-Verification Settings Guidelines
SMILE Jhns Hpkins University Baltimre, MD USA Rche Mdular Aut-Verificatin Settings Guidelines Rche Mdular Aut Verificatin Settings Guideline Number Equ2.9-02-G Authrs: Penny S. Stevens & Kurt L. Michael
More informationLyme Disease Surveillance in North Carolina
Lyme Disease Surveillance in Nrth Carlina 2008-2014 Carl Williams DVM Megan Sanza MPH Cmmunicable Disease Branch Divisin f Nrth Carlina Public Health Lyme Disease Surveillance in Nrth Carlina 2008-2014
More informationMedical Student Immunization Requirements
Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German
More information2018 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 24 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More informationMemory Care Community Standards
Memry Care Cmmunity Standards SEXUAL / INTIMATE BEHAVIOR POLICY Staff shuld understand, recgnize and supprt the healthful expressin f sexuality and intimacy amng residents, and demnstrate an understanding
More informationNCI Version Date: (194) NSABP B-55/BIG 6-13
Figure 1 Study Flw Chart ICF fr patients with unknwn BRCA status t underg central BRCA testing during, r prir t, neadjuvant/adjuvant chemtherapy Neadjuvant chemtherapy Minimum 6 cycles (cntaining anthracyclines,
More informationIowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training
Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.
More informationImaging tests allow the cancer care team to check for cancer and other problems inside the body.
IMAGING TESTS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between yu
More informationNutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:
Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin
More informationNational Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes
Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.5 Cmpleted: June 14, 2018 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationEvaluation of a Shared Decision Making Intervention between Patients and Providers to Improve Menopause Health Outcomes: Issue Brief
Evaluatin f a Shared Decisin Making Interventin between Patients and Prviders t Imprve Menpause Health Outcmes: Issue Brief Key Findings Tablet technlgy can be successfully incrprated int primary practices
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationChild s Name: Date of Birth: TAKE THIS SHEET TO EVERY DOCTOR S APPOINTMENT
Date f Birth: TAKE THIS SHEET TO EVERY DOCTOR S APPOINTMENT Prtable Medical Summary Name: Date Updated: / / Address: Phne: Mbile: E-mail: DOB: SSN: - - Allergies: Pertinent Persnal Characteristics: What
More informationName of procedure: Removal of submandibular salivary gland
Oral facial surgery Surgical prcedure infrmatin leaflet Name f prcedure: Remval f submandibular salivary gland This leaflet explains sme f the benefits, risks and alternatives t the peratin. We want yu
More informationCnsideratin fr Optimizatin: Optimizatin is a prgram transfrmatin technique, which tries t imprve the cde by making it cnsume fewer resurces (i.e. CPU, Memry) and deliver high speed. In ptimizatin, high-level
More information